Kahalalide F vs Apratoxin A
Head-to-head comparison of Kahalalide F (Kahalalide F) and Apratoxin A (Apratoxin A) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Kahalalide F | Apratoxin A |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Kahalalide F | Apratoxin A |
| Molecular Weight | 1111.3 Da | N/A |
| Half-Life | N/A | N/A |
| Amino Acids | N/A | N/A |
| Typical Dose | 0.1-3 mg/m2 IV in early trials | N/A in humans; nanomolar in vitro |
| Route | Intravenous | Intraperitoneal / Intravenous (preclinical) |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 140 |
| Research Status | Pre-clinical | Pre-clinical |
Kahalalide F Benefits
- ✓antineoplastic
- ✓pro-apoptotic
- ✓membrane-active
- ✓anti-proliferative
Apratoxin A Benefits
- ✓antineoplastic
- ✓anti-angiogenic
- ✓Sec61 inhibition
- ✓anti-proliferative
Kahalalide F Dosing
IV infusion in phase I oncology studies|dose escalation used in trials|preclinical nanomolar assays
Apratoxin A Dosing
preclinical in vitro nanomolar use|animal studies only|no human dosing established
Kahalalide F Side Effects
- ⚠fatigue
- ⚠nausea
- ⚠transaminase elevation
Apratoxin A Side Effects
- ⚠hepatotoxicity
- ⚠general cytotoxicity
- ⚠GI toxicity
Research Overview
Kahalalide F
Kahalalide F was investigated in multiple preclinical and early clinical cancer studies because of its unusual membrane-disrupting and anti-tumor effects. Development highlighted the promise and limits of marine depsipeptides as oncology leads.
Apratoxin A
Apratoxin A is a well-studied lead compound for targeting secretory and membrane protein biogenesis in cancer cells. Medicinal chemistry programs around apratoxins focus on improving selectivity and reducing hepatotoxicity while preserving potency.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.